Last reviewed · How we verify
Postoperative ileus — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Entereg | ALVIMOPAN | Cubist Pharms | Opioid Antagonist | µ-opioid receptor | 2008-01-01 | |
| Entereg | Entereg | Hartford Hospital | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Cubist Pharms · 1 drug in Postoperative ileus
- Hartford Hospital · 1 drug in Postoperative ileus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Postoperative ileus:
- Postoperative ileus treatment updates — RSS
- Postoperative ileus treatment updates — Atom
- Postoperative ileus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Postoperative ileus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postoperative-ileus. Accessed 2026-06-10.
Related
- Postoperative ileus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing